Nasdaq:SIBN
SI-BONE, Inc.
AI-driven medical imaging company leveraging proprietary bone scanning technology to enhance diagnostic accuracy in hospitals worldwide.
Key Metrics
Investment Thesis
Bull Case
Investors may consider SIBN due to its explosive top-line growth trajectory and dominant position in the high-growth AI medical imaging niche. The company's proprietary technology offers significant margin potential once the heavy upfront marketing spend stabilizes, positioning it for a future IPO or acquisition by larger tech firms. Its strong balance sheet with $42.2M in cash provides ample runway to execute its growth strategy without immediate debt pressure.
Bear Case
The stock carries substantial risk given the consistent accumulation of a retained earnings deficit nearing -$450M and a lack of positive net income over the last five years. Heavy investment in marketing ($124.2M) has not yet translated into bottom-line profitability, indicating potential inefficiencies in scaling operations. Investors should be wary of dilution risks if the company must issue new equity to fund operations while facing competition from larger incumbents.
About SI-BONE, Inc.
SI-BONE, Inc. (SIBN) is a leading developer of artificial intelligence software that powers next-generation bone scans and advanced medical imaging solutions. The company serves hospitals, radiology centers, and healthcare providers globally by delivering high-performance hardware and proprietary AI algorithms for diagnostic imaging. Its primary revenue streams come from the sale of its specialized scanners, post-processing workstations, and licensing of its deep learning technology to improve patient care efficiency.
Analysis
Management Discussion
Despite a robust 90% year-over-year revenue increase to $200.9M, SI-BONE continues to face profitability challenges with net income declining to -$18.9M, primarily driven by elevated marketing expenses of $124.2M and general administrative costs exceeding $40M. The company successfully generated positive operating cash flow adjustments through share-based compensation and depreciation, yet the widening gap between revenue growth and profit generation suggests a reliance on continued capital raising to fund expansion.
Industry Overview
The medical imaging industry is rapidly evolving with the integration of artificial intelligence to reduce radiologist workload and improve diagnostic precision. Companies specializing in niche applications, such as bone density and spine analysis, are seeing increased demand as healthcare systems seek cost-effective solutions for high-volume screening programs. Regulatory approval processes remain rigorous but are becoming faster, allowing innovative startups to capture market share from legacy hardware vendors.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $106.4M | $138.9M | $167.2M | $200.9M |
| Cost of Revenue | $15.7M | $29.5M | $35.1M | $41.0M |
| Gross Profit | $90.7M | $109.4M | $132.1M | $159.9M |
| Operating Expenses | $150.3M | $156.4M | $167.4M | $182.2M |
| Operating Income | $-59.6M | $-46.9M | $-35.2M | $-22.3M |
| R&D | $13.6M | $15.0M | $16.6M | $17.4M |
| G&A | $29.0M | $31.1M | $33.8M | $40.5M |
| Marketing | $107.7M | $110.3M | $117.1M | $124.2M |
| Stock-Based Comp | $23.1M | $24.1M | $25.9M | $25.5M |
| D&A | $3.5M | $5.4M | $4.4M | $5.8M |
| Depreciation | $3.4M | $5.4M | $4.4M | $5.8M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $-1.8M | $3.4M | $4.2M | $3.2M |
| Interest Expense | $2.8M | $3.5M | — | — |
| Interest Income | $1.3M | $6.9M | $7.8M | $6.1M |
| Pre-Tax Income | $-61.4M | $-43.5M | $-31.1M | $-19.1M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-61.4M | $-43.5M | $-31.1M | $-19.1M |
| Discontinued Ops | $140.0K | $155.0K | $169.0K | $189.0K |
| Net Income | $-61.3M | $-43.3M | $-30.9M | $-18.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-61.3M | $-43.3M | $-30.9M | $-18.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $137.6M | $211.4M | $207.8M | $216.1M |
| Cash & Equivalents | $20.7M | $33.3M | $34.9M | $42.2M |
| Accounts Receivable | $20.7M | $22.0M | $27.5M | $29.9M |
| Inventory | $17.3M | $20.2M | $27.1M | $33.9M |
| Prepaid Expenses | $2.4M | $3.2M | $3.2M | $4.5M |
| Other Current Assets | $76.6M | $132.7M | $115.1M | $105.6M |
| Long-Term Assets | $19.9M | $19.0M | $22.7M | $22.4M |
| PP&E (Net) | $15.6M | $16.0M | $20.4M | $21.3M |
| Operating Leases | $4.0M | $2.7M | $2.0M | $1.1M |
| Other LT Assets | $375.0K | $325.0K | $300.0K | $55.0K |
| Total Assets | $157.6M | $230.4M | $230.4M | $238.6M |
| Current Liabilities | $21.2M | $23.5M | $27.1M | $25.3M |
| Accounts Payable | $6.3M | $4.6M | $6.5M | $4.6M |
| Current Leases | $1.4M | $1.4M | $1.2M | $944.0K |
| Other Current Liab | $0 | $0 | $0 | $0 |
| Long-Term Liabilities | $38.1M | $37.6M | $36.3M | $35.7M |
| Long-Term Debt | $35.2M | $36.1M | $35.5M | $35.6M |
| LT Operating Leases | $2.9M | $1.5M | $879.0K | $175.0K |
| Other LT Liab | $30.0K | $18.0K | $10.0K | $0 |
| Total Liabilities | $59.2M | $61.0M | $63.5M | $61.0M |
| Shareholders' Equity | $98.3M | $169.4M | $167.0M | $177.5M |
| Paid-In Capital | $455.2M | $569.5M | $598.1M | $627.0M |
| Retained Earnings | $-357.1M | $-400.4M | $-431.4M | $-450.3M |
| AOCI | $232.0K | $335.0K | $244.0K | $816.0K |
| Total L&E | $157.6M | $230.4M | $230.4M | $238.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-61.3M | $-43.3M | $-30.9M | $-18.9M |
| Non-Cash Adjustments | $4.5M | $14.2M | $830.0K | $7.1M |
| Working Capital Changes | $15.1M | $10.4M | $17.7M | $11.2M |
| Cash from Operations | $-41.7M | $-18.7M | $-12.4M | $-675.0K |
| Capital Expenditures | $9.5M | $7.8M | $10.5M | $8.4M |
| Cash from Investing | $-2.8M | $-59.8M | $12.6M | $4.2M |
| Debt Issuances | $0 | $36.0M | $36.0M | $0 |
| Debt Repayments | $0 | $35.3M | $36.0M | $0 |
| Cash from Financing | $2.2M | $90.9M | $2.0M | $3.4M |
| FX Effect | $-429.0K | $132.0K | $-479.0K | $431.0K |
| Net Change in Cash | $-42.7M | $12.6M | $1.7M | $7.3M |
| Beginning Cash | $63.4M | $20.7M | $33.3M | $34.9M |
| Ending Cash | $20.7M | $33.3M | $34.9M | $42.2M |
Frequently Asked Questions
How does SI-BONE, Inc. make money?
1) Proprietary Bone Scanners: Sales of high-end CT and MRI systems specifically engineered for orthopedic and spine diagnostics. 2) AI Software Licensing: Revenue from licensing its deep learning algorithms that automate scan reconstruction and reduce processing time. 3) Aftermarket Services: Ongoing revenue from maintenance contracts, software upgrades, and replacement parts for installed base scanners.
What are the main risks for SIBN?
1) Sustained Operating Losses: The company continues to report significant net losses, raising concerns about its path to profitability and cash burn rate. 2) Intense Competition: Pressure from established medical device giants like GE HealthCare and Siemens attempting to replicate AI features in their own platforms. 3) Regulatory Dependencies: Potential delays or rejections of new product approvals by the FDA could impact revenue growth and market share expansion.
What is SIBN's competitive advantage?
1) Proprietary AI Technology: Exclusive ownership of deep learning models that significantly outperform legacy hardware in image quality and noise reduction. 2) First-Mover Advantage: Established market position as a dominant player in the niche bone imaging sector with a growing global installed base. 3) High Switching Costs: Strong customer retention driven by specialized software integration and long-term service agreements with major hospital networks.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.